Sichuan Kelun-Biotech Receives NMPA Approval for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer
I'm PortAI, I can summarize articles.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) in China for its antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), to treat adult patients with unresectable or metastatic HR+/HER2- breast cancer who have undergone at least one prior systemic therapy. This is the fourth approved indication for sac-TMT by the NMPA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments